Corticosteroid chronic respiratory diseases with risk of aspergillosis

• Autores: Cristina Martínez Roca, Hector José Mozo Peñalver
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 4, 2013, págs. 286-289
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To analyze the voriconazole prescriptions and define prognosis and the risk factors of developing necrotizing pulmonary aspergillosis in patients with chronic respiratory disease. Method: A one-year retrospective observational study. Data sources: pharmacologic and clinical records. Data: age, sex, diagnosis and co-morbidities, symptoms, therapies, previous admissions, radiological and microbiological reports and prognosis. Results: Nine patients (six females and three males, 72.5 ±4.6 years) were diagnosed with necrotizing pulmonary aspergillosis and required treatment with voriconazole (mean of treatment duration 29 ±17 days). Risk factors: prolonged use of corticosteroids; broad-spectrum antibiotic therapy; prior hospitalization in the last six months; pulmonary disorders; comorbidities. We observed that 11% of mortality was related to the process. Conclusion: The incidence of pulmonary aspergillosis in patients with chronic lung disease has been possibly underestimated. It is important to clarify the meaning, incidence and consequences of Aspergillus colonization in patients with chronic lung disease